Please login to the form below
neurodegeneration
This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.
Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal
assets,” said Mark Mintun, vice president of pain and neurodegeneration research at Lilly.
Latest news
-
Lilly buys biotech firm Disarm Therapeutics for $135m
The scientific team at Disarm discovered an important and highly promising approach to combat axonal degeneration,” said Mark Mintun, vice president of pain and neurodegeneration research at Lilly. ... Lilly has previously tried its hand in
-
Calliditas bets on PBC drug in Genkyotex buyout
Genkyotex’s platform identifies small molecules which can selectively inhibit specific NOX enzymes that amplify multiple disease processes including fibrosis, inflammation, pain processing, cancer development and neurodegeneration.
-
Biogen pays Denali $1bn upfront for Parkinson’s disease programme
Mutations in the LRRK2 gene, a regulator of lysosomal function, can cause Parkinson’s disease and is thought to contribute to neurodegeneration.
-
Merck acquires pre-clinical biotech Calporta for up to $576m
Expands into early-stage neurodegeneration research field. Merck has taken a stake in the neurodegeneration research field, following the acquisition of San-Diego, US-based Calporta. .
-
New data backs GeNeuro’s MS drug after Servier exit
GeNeuro opted to continue dosing patients in the open-label follow-up, and now says temelimab provided continued relative improvements in neurodegeneration measured by magnetic resonance imaging (MRI), including a reduction
More from news
Approximately 2 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
A roadmap to the successful treatment of Alzheimer’s disease
Two proteins – Tau and beta-amyloid – are recognised as major hallmarks of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells and spread between cells, while ... Secondly, it is well understood that
-
Brain power: fresh approaches to Alzheimer’s drug discovery
US biotech company Alector, which is pioneering work in immuno-neurology and novel therapeutic approaches to treating neurodegeneration, raised $176m in an initial public offering in early February. ... Alector has devoted the last five years to the
-
Deal Watch October 2018
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
-
Key considerations for disease- modifying Parkinson’s disease trials
dopamine due to neurodegeneration.
-
Holding on to hope for Alzheimer’s advances
abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination…it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Lilly strengthens team with in-house promotions
Importantly, this team will help us maintain focus as we work to bring forward new medicines in diabetes, cancer, immunology, neurodegeneration and pain.”.
-
Asceneuron appoints chief medical officer
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.
-
Nouscom appoints COO and board members
Prior to this, she was the global head of neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey &Company in Chicago.
-
Polleo Pharma co-founders join Chronos Therapeutics
Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.
-
Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research
including neurodegeneration, neuroinflammation and central nervous system inherited diseases.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Are we ready for an Alzheimer's disease modifying treatment
As it is easier to prevent neurodegeneration (neuron death) than to reverse it, neuroscientists are starting to look for early markers, through genetic tests or blood tests, in order to diagnose
-
Innovative approaches in the treatment of multiple sclerosis
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
-
Innovative approaches in the treatment of multiple sclerosis
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Communique - Communiqué Awards
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
Attigo (part of the Mednet Group)
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
